Metastatic Castration-Resistant Prostate Cancer: Treatment Selection and Sequencing With Tanya Dorff, MD

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primar...
Continue reading

Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON

Veno-occlusive disease (VOD) is a potentially life-threatening complication of hematopoietic stem cell transplant. In patients with severe cases, the mortality rate has been estimated to be greater than 80%. In this exclusive interview, Phyllis McKiernan, APN, MSN, OCN and Michelle Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON spoke with i3 Health about challenges, patient education strategies, and best practices in nursing management of adult and pediatric patients with VOD.​

Continue reading

What do you consider "sorafenib failure?" Progression on radiological evaluation, clinical evaluation, or both?

Thomas A. Abrams, MD: Clinical deterioration that is not related to obvious AEs of sorafenib has to be regarded as a progression or sorafenib failure, especially if there's corroborating evidence such as biochemical worsening, AFPs going up, worsening liver function, or ascites. Those could be used as a surrogate to progression. If radiological data suggest that the disease is getting worse with new or enlarged lesions, worsening portal venous thrombus, or worsening liver function due to increas...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.